CEO Stephen Isaacs describes Aduro Biotech Inc.'s recently signed immuno-oncology collaboration with Stanford University as an effort to join wheels to a car, "so hopefully we can go on a very nice journey together."
The agreement, announced Jan. 17, will combine Aduro's personalized live, attenuated double-deleted Listeria (LADD) immunotherapy platform with an algorithm developed...








